Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents

Sokal, Étienne; Bourgois, Annick; Stéphenne, Xavier; Silveira, Themis Reverbel da; Porta, Gilda; Gardovska, Dace; Fischler, Björn; Kelly, Déirdre

doi:10.1016/j.jhep.2010.01.028

Cited by 99 publications

(107 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some experts prefer starting treatment earlier as there is better treatment response and tolerability of PEG‐IFN and ribavirin in children compared with adults 144, 145. This may be especially relevant for patients with HCV genotypes 2 and 3, for whom sustained virological response with PEG‐IFN and ribavirin over 24 weeks is much better than for genotype 1 (sustained virological response in HCV‐monoinfected children 89–93% 146, 147. However, PEG‐IFN has an adverse effect on growth in children, and the risk−benefit ratio should be carefully considered during growth spurts 148.…”

Section: Coinfectionsmentioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV‐1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short‐term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long‐term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first‐ and second‐line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

show abstract

Section: Coinfectionsmentioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The application of this therapy in children was approved by the Food and Drug Administration in December 2008 and by the European Agency for the evaluation of Medicinal products in november 2009. This therapy is very effective and secures a high quality of life for the patient, which is very important, especially in the case of children (2,4,5).…”

Section: Introductionmentioning

confidence: 99%

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

Pawłowska¹,

Pilarczyk

Foksinska

et al. 2011

Hepat Mon

View full text Add to dashboard Cite

Article type: original ArticleBackground: Treatment of hepatitis C virus (HCV) infection with interferon (IFn) and ribavirin (RBV) is associated with adverse events, which may affect the patient's adherence to the treatment regimen and the treatment efficacy. Objectives: The aim of this study was to assess the sustained viral response (SVR) and interdependence between the haematological characteristics (leukocyte count, platelet count, and haemoglobin levels) in patients with chronic hepatitis C (CHC) infection during treatment with IFn and RBV. Patients and Methods:We conducted a retrospective cohort study of 170 children with CHC infection who completed treatment with IFn-α and RBV. The children were divided into 2 groups: the first group (group I, n = 119) underwent a 48-week course of treatment with recombinant IFn α-2b (Intron A) at a dosage of 3 MU 3 times a week subcutaneously and RBV at a dosage of 15 mg/kg per day orally, and the second group (group II, n = 51) was administered pegylated IFn (peg-IFn)-α-2b (pegIntron) at a dosage of 1.5 µg/kg per week subcutaneously and RBV at a dosage of 15 mg/kg per day orally for 48 weeks. The dose of IFn was not adjusted but that of ribavirin was in 2 children from group II. Hematological growth factors and erythropoietin were not used. SVR was defined as undetectable serum HCV RnA 24 weeks after the end of treatment (study week 72). Serum HCV RnA was determined by performing polymerase chain reaction, and the HCV genotypes and hematological parameters were evaluated. Serum HCV RnA levels were analysed by descriptive statistics. Means and standard deviations were calculated for values collected at the baseline, on the 12th and 48th weeks during treatment, and after 24 weeks of untreated follow-up (study week 72). Results: eighty-six (50%) of the 170 patients who underwent treatment achieved SVR: 62 (51%) out of 119 children from group I and 24 (47%) out of 51 from group II. The mean serum hemoglobin levels and leukocyte and platelet counts at week 12 were significantly lower than the baseline values in both responders and non-responders from both the groups (P < 0.05). In the responders in group I, the mean levels of serum hemoglobin after 24 weeks of treatment and at the end of therapy were significantly lower than the mean levels at baseline. In the group treated with peg-IFn-α-2b and RBV (group II), the mean serum hemoglobin levels at week 12 was lower in the responders than in the non-responders (P < 0.05). The decrease in the hemoglobin levels was associated with viral response. In both the responders and nonresponders from both the groups, leukocyte counts decreased during treatment, and after 12 weeks, they were more significantly lower than the baseline value. The decrease was more marked in children treated with peg-IFn-α-2b + RBV (P < 0.05). After 12 weeks of treatment, the platelet count was low in children from group II who had achieved SVR. Conclusions: A mild decrease in hemoglobin levels and leukocyte and platelet counts during treatment with IFn and ...

show abstract

“…Data regarding phenotype and topography of HPC activation vary among different studies. A ductular reaction at the limiting plate of portal tracts and septa has been invariably identified [1,8,12,26,27]. Diverse observations have been also reported regarding the intraparenchymal HPC [1].…”

Section: Discussionmentioning

confidence: 99%

Hepatic Progenitor Cells and Cells Resistant to Apoptosis in Chronic HCV

Elsabaawy¹,

Abdelsameea²,

Abdallah³

et al. 2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

show abstract

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents

Cited by 99 publications

References 26 publications

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

Hepatic Progenitor Cells and Cells Resistant to Apoptosis in Chronic HCV

Contact Info

Product

Resources

About